Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays - PubMed (original) (raw)
Review
. 2009 Oct:18 Suppl 3:S141-5.
doi: 10.1016/S0960-9776(09)70290-5.
Affiliations
- PMID: 19914534
- DOI: 10.1016/S0960-9776(09)70290-5
Free article
Review
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays
Kathy S Albain et al. Breast. 2009 Oct.
Free article
Abstract
Background: Multigene assays performed on the primary tumors from women with non-metastatic breast cancer provide useful prognostic information and discriminate excellent versus poor outcome potential in diverse clinical scenarios. Recently, analyses were conducted to determine if these assays predict who benefits from adjuvant chemotherapy added to endocrine therapy and conversely, who might avoid chemotherapy because of lack of substantial benefit. This literature-based review summarizes these data and provides a perspective on the limitations and clinical utility of these assays.
Methods: The literature regarding multigene assays and signatures in early breast cancer was surveyed. Only two assays-- the 21-gene recurrence score (RS) assay (Oncotype DX) and the 70-gene signature (MammaPrint)--were analyzed in randomized or non-randomized clinical populations in order to determine the predictive utility of the test in the adjuvant chemotherapy setting in patients whose tumors were estrogen-receptor positive. These data are summarized by type of clinical analysis, with information on clinical utility and comparative studies with standard clinical-pathologic factors.
Results: From 2 independent analyses in phase III clinical trial settings with tamoxifen-alone control arms, the 21-gene RS assay defines a group of patients with low scores who do not appear to benefit from chemotherapy, and a second group with very high scores who derive major benefit from CMF or CAF chemotherapy. One study was conducted in node-negative disease, and the second in a node-positive population. Interaction terms were significant in both studies, and the effect of the assay remained upon adjustment for other standard factors. Utilizing a non-randomized clinical setting, the 70-gene signature could also predict chemotherapy benefit in the high risk group, versus no apparent benefit in the low risk group, an effect that remained after adjustment for standard factors. For both assays, the discordance rate between the assay prediction and clinical-pathologic risk category was approximately 30%. Clinical utility studies showed use of the assay results in a change in treatment decision in 25-30% of cases, most commonly from chemoendocrine therapy to endocrine therapy alone.
Summary: The prediction of adjuvant chemotherapy benefit over and above endocrine therapy using multigene assay-determined risk category differs greatly across risk level and challenges the previous adjuvant therapy paradigm that degree of benefit is the same regardless of risk. These data justify current clinical use of these assays, while ongoing prospective studies will refine their role in practice settings.
Similar articles
- Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Viale G, et al. J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393. J Clin Oncol. 2008. PMID: 18349391 Clinical Trial. - Adjuvant therapy for breast cancer.
[No authors listed] [No authors listed] NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. NIH Consens Statement. 2000. PMID: 11512506 Review. - Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31. Breast Cancer Res Treat. 2009. PMID: 18668363 Clinical Trial. - Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M. Gasparini G, et al. Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11. Cancer J Sci Am. 1999. PMID: 10198732 Clinical Trial. - Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS. Ross JS. Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Adv Anat Pathol. 2009. PMID: 19546609 Review.
Cited by
- Optimizer's dilemma: optimization strongly influences model selection in transcriptomic prediction.
Crawford J, Chikina M, Greene CS. Crawford J, et al. Bioinform Adv. 2024 Jan 24;4(1):vbae004. doi: 10.1093/bioadv/vbae004. eCollection 2024. Bioinform Adv. 2024. PMID: 38282973 Free PMC article. - Determinants of response to CDK4/6 inhibitors in the real-world setting.
Witkiewicz AK, Schultz E, Wang J, Hamilton D, Levine E, O'Connor T, Knudsen ES. Witkiewicz AK, et al. NPJ Precis Oncol. 2023 Sep 13;7(1):90. doi: 10.1038/s41698-023-00438-0. NPJ Precis Oncol. 2023. PMID: 37704753 Free PMC article. - Biomarkers in Breast Cancer: An Old Story with a New End.
Neves Rebello Alves L, Dummer Meira D, Poppe Merigueti L, Correia Casotti M, do Prado Ventorim D, Ferreira Figueiredo Almeida J, Pereira de Sousa V, Cindra Sant'Ana M, Gonçalves Coutinho da Cruz R, Santos Louro L, Mendonça Santana G, Erik Santos Louro T, Evangelista Salazar R, Ribeiro Campos da Silva D, Stefani Siqueira Zetum A, Silva Dos Reis Trabach R, Imbroisi Valle Errera F, de Paula F, de Vargas Wolfgramm Dos Santos E, Fagundes de Carvalho E, Drumond Louro I. Neves Rebello Alves L, et al. Genes (Basel). 2023 Jun 28;14(7):1364. doi: 10.3390/genes14071364. Genes (Basel). 2023. PMID: 37510269 Free PMC article. Review. - Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.
Knudsen ES, Schultz E, Hamilton D, Attwood K, Edge S, O'Connor T, Levine E, Witkiewicz AK. Knudsen ES, et al. Oncologist. 2022 Aug 5;27(8):646-654. doi: 10.1093/oncolo/oyac089. Oncologist. 2022. PMID: 35666660 Free PMC article. - Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers.
Barrón-Gallardo CA, Garcia-Chagollán M, Morán-Mendoza AJ, Delgadillo-Cristerna R, Martínez-Silva MG, Aguilar-Lemarroy A, Jave-Suárez LF. Barrón-Gallardo CA, et al. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338211068965. doi: 10.1177/15330338211068965. Technol Cancer Res Treat. 2022. PMID: 34981997 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical